Adakveo (crizanlizumab) PRegnancy outcomes Intensive Monitoring (PRIM) (Adakveo (crizanlizumab) PRIM)

First published 18/02/2021

Last updated 08/05/2024

EU PAS number:

EUPAS39412

Study

Ongoing

Download as PDF

Documents

Study protocol

Initial protocol

Protocol_SEG101 PRIM_10July2020_clean_Redacted

English (364.16 KB - PDF)View document

Study results

Study report

Other information